Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global in-vitro colorectal cancer screening tests market size was valued at USD 920.4 million in 2024, with Europe holding a significant market share. The market is driven by the rising prevalence of colorectal cancer across the region. It is expected to grow at a CAGR of 5.53% during the forecast period of 2025-2034, with the values likely to attain USD 1492.8 million by 2034.
Colorectal cancer is the third most common cancer across the globe. It claims nearly 10% of all cancer cases and is the second leading cause of cancer-related deaths worldwide. According to the World Health Organization, in 2020, more than 1.9 million new cases of colorectal cancer were recorded globally. Europe, Australia, and New Zealand experienced the highest incidence rates, and the mortality rates were highest in Eastern Europe. It is expected that the burden of colorectal cancer will increase to 3.2 million new cases per year (an increase of 63%) by 2040, and 1.6 million deaths per year (an increase of 73%).
Europe in-vitro colorectal cancer screening tests market share is expected to be elevate with increasing strategic moves of market players. Considering the urgency of diagnosing colorectal cancer in its early stages with accuracy, there have been dedicated efforts to develop effective products. On January 9, 2024, a clinical-stage diagnostics company Dxcover Limited, pioneering in multi-omic spectral analysis (MOSA) for the early detection of multiple cancers, announced the initiation of three pivotal clinical trials, measuring the efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal, and lung cancer. Their CREATE2 trial is focused on evaluating the diagnostic accuracy for colorectal cancer and high-risk adenoma in patients who have been going through colonoscopy. With colorectal cancer already difficult to diagnose in early detection screenings, diagnosis at these stages will enable positive patient outcomes.
Europe in-vitro colorectal cancer screening tests market growth is anticipated to be positively impacted by the researchers innovating new testing methods for the detection of precursors of colorectal cancer. For instance, in February 2024, researchers at the Netherlands Cancer Institute, Amsterdam UMC, and Erasmus MC developed a new test, titled multitargetFIT-test (mtFIT). With the existing FIT test, the patient’s stool is analysed for hemoglobin, however mtFIT measures hemoglobin and two additional proteins. mtFIT is targeted to detect cancer precursors more effectively. Notable outcomes have also been registered in a large prospective study, in which mtFIT effectively detected cancer precursors in comparison to the current FIT. Based on the diagnostic test guidelines in Europe, the next step is to produce the mtFIT test on a larger industrial scale. This is because the test can be included in existing FIT-based screening programs, as the screening logistics requirements are similar. To facilitate the availability of the test for CRC screening participants in the Netherlands and other places, a company called CRCbioscreen has also been established.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup | Categories |
Testing Type | Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Flexible Sigmoidoscopy, Others |
Imaging Type | Colonoscopy, Proctoscopy, CT scan, Ultrasound, MRI, PET Scan |
End User | Hospitals, Clinics, Diagnostics Laboratories |
Country | United Kingdom, Germany, France, Italy, Others |
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2018-2024 |
Forecast Period | 2025-2034 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Testing Type |
|
Breakup by Imaging Type |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Europe In-Vitro Colorectal Cancer Screening Tests Market Size
Europe In-Vitro Colorectal Cancer Screening Tests Market Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The Europe in-vitro colorectal cancer screening tests market is expected to be driven by the increasing research activities in the global market, which is anticipated to grow at a CAGR of 5.53% during the forecast period of 2025-2034, and is likely to reach a market value of USD 1492.8 million by 2034.
Factors aiding the market demand include increasing prevalence of colorectal cancer along with market players understanding the importance of urgent requirements for new and effective screening tests for early detection of cancer.
Major trends influencing the market growth include researchers innovating new testing methods for detecting colorectal cancer precursors. For instance, in February 2024, researchers at the Netherlands Cancer Institute, Amsterdam UMC, and Erasmus MC developed a new test, called multitargetFIT-test (mtFIT).
Based on the testing type, the market is segmented into fecal occult blood tests, biomarker tests, CRC DNA screening tests, and flexible sigmoidoscopy, among others.
By imaging type, the market is divided into colonoscopy, proctoscopy, CT scan, ultrasound, MRI, and PET scan, among others.
End users of the market are hospitals, clinics, and diagnostics laboratories.
The market segmentation by countries includes the United Kingdom, Germany, France, Italy and others.
The key players in the market are Epigenomics AG, NOVIGENIX SA, Merck KGaA, Abbott, Siemens Healthineers AG, Sysmex Corporation, F. Hoffmann-La Roche Ltd, Eiken Chemical Co., Ltd., Beckman Coulter, Inc., and Qiagen NV.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share